Journals / Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi / 2013 / Cilt: 27 - Sayı: 1

Free oxygen radicals in drug-induced nephrotoxicity

İlaca bağlı nefrotoksisitede serbest oksijen radikalleri

Pages
51–56
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recognizing the risk factors and obtaining of information regarding the pathophysiology of nephrotoxicity are the first step in reducing the renal injury related to drugs and toxins.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Many of the patients with drug-induced nephrotoxicity have risk factors that lead to the damage.
📊
Key Findings & Data:Among these factors, there are patient, kidney and drug-specific risk factors.
💡
Conclusion & Impact:Recognizing the risk factors and obtaining of information regarding the pathophysiology of nephrotoxicity are the first step in reducing the renal injury related to drugs and toxins.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Many of the patients with drug-induced nephrotoxicity have risk factors that lead to the damage. Among these factors, there are patient, kidney and drug-specific risk factors. All compartments of the kidney can be affected and results in one or more clinical renal pathologies include acute or chronic kidney disease, various tubulopathies and proteinuric renal disease. Treatment plan depends on how to create a form of toxicity. The toxic effect of the some nephrotoxic agents on kidney is realized by creating an oxidative stress atmosphere. It is well established that antioxidant therapy reduced possible damage caused by toxic agents in experimental conditions. Recognizing the risk factors and obtaining of information regarding the pathophysiology of nephrotoxicity are the first step in reducing the renal injury related to drugs and toxins.

Özet

İlaca bağlı nefrotoksisitenin ortaya çıktığı kişilerin çoğunda, hasarın yatkınlığına sebep olan risk faktörleri bulunmaktadır. Bunlar hastaya, böbreğe ve ilaca spesifik risk faktörleridir. Nefrotoksisite böbreğin bütün kısımlarını etkileyebilir ve bu durum akut ya da kronik böbrek hastalığı, çeşitli tübülopatiler ve proteinürik böbrek hastalıklarını içeren bir ya da daha fazla klinik böbrek patolojileri ile sonuçlanabilir. Tedavi planı, nefrotoksik ajanın toksisiteyi oluşturma mekanizmasına bağlıdır. Bazı ajanların böbrekteki toksik etkisi oksitadif stres ortamı oluşturarak gerçekleşmektedir. Deneysel koşullarda antioksidan tedavinin toksik ajanlara karşı oluşabilecek muhtemel hasarı azalttığı iyi bilinmektedir. Risk faktörlerini tanımlamak ve nefrotoksisite patofizyolojisi hakkında bilgi sahibi olmak, ilaca ve toksinlere bağlı böbrek hasarının azaltılmasında ilk adımdır.

🔖

Cite This Article

PARLAKPINAR, H., ÖRÜM, M. H., ACET, A. (2022). Free oxygen radicals in drug-induced nephrotoxicity. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi, Cilt: 27 - Sayı: 1, 51–56. https://ajindex.com/articles/514659

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Pfaller W, Gstraunthaler G. Nephrotoxicity testing in vitro-- what we know and what we need to know. Environ Health Perspect 1998; 106: 559-569
  2. Perazella MA. Renal Vulnerability to Drug Toxicity. Clin J Am Soc Nephrol 2009; 4: 1275–1283
  3. Brady HR, Brenner BM. Acute Renal Failure. Harrison's Principles of Internal Medicine 13th Ed. Vol.2, (Eds) Wilson JD, Braunwald E, Isselbacher KJ, et al. New York, St. Louis, San Francisco, Colorado Springs, Auckland, Bogota
  4. Guder WG, Morel F. Biochemical characterization of individual nephron segments. In: Handbook of Physiology. Section 8: Renal Physiology, London, 1992
  5. Jones DP. Renal metabolism during normoxia, hypoxia and ischemic injury. Annu Rev Physiol 1988; 48: 33-50
  6. McFarlane M, Foster RJ, Gibson GG, et al. Cysteine conjugate f3-lyase of rat kidney cytosol: characterisation, immunocytochemical localization, and correlation with hexachlorobutadiene nephrotoxicity. Toxicol Appl Pharmacol 1989; 98: 185-197
  7. Elseviers MM, DeBroe ME. Analgesic nephropathy: Is it caused by multi-analgesic abuse or single substance use? Drug Saf 1999; 20: 15–24
  8. Rougier F, Ducher M, Maurin M, et al. Aminoglycoside dosages and nephrotoxicity. Clin Pharmacokinet 2003; 42: 493–500
  9. Lamieire NH, Flombaum CD, Moreau D, et al. Acute renal failure in cancer patients. Ann of Med 2005; 37: 13–25
  10. Briguori C, Colombo A, Airoldi F, et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: Impact of N-acetylcysteine. Kidney Int 2005; 68: 2250– 2255
  11. Van Vleet TR, Schnellmann RG. Toxic nephropathy: Environmental chemicals. Semin Nephrol 2003; 23: 500– 508
  12. Leblanc M, Kellum JA, Gibney RT, et al. Risk factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit Care 2005; 11: 533-536
  13. Kaufman J, Dhakal M, Patel B, et al. Community-acquired acute renal failure. Am J Kidney Dis 1991; 17: 191-198
  14. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930-936
  15. Hoste EA, Kellum JA. Acute kidney injury: epidemiology and diagnostic criteria. Curr Opin Crit Care 2006; 12: 531- 537
  16. Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med 2002; 69: 289-90
  17. Parlakpınar H, Örüm MH, Acet A. Kafeik Asit Fenetil Ester (KAFE) ve Miyokardiyal İskemi Reperfüzyon (Mİ/R) Hasarı. İnönü Üniversitesi Sağlık Bilimleri Dergisi 2012; 1: 10-5
  18. Parlakpinar H, Tasdemir S, Polat A, et al. Protect